Physician profile
George E Morgan
NPI 1649387051
$530.15
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.15 · 2020: $19.85 · 2022: $84.84 · 2023: $273 · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $101.19 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $78.06 | 2023-2024 | Stelara |
| Abbvie INC. | $64.28 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.32 | 2020-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $41.17 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $30.07 | 2023 | Dificid |
| Pfizer INC. | $26.19 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2023 | Cyltezo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.85 | 2022 | |
| Lilly USA, LLC | $21.45 | 2024 | Omvoh |
| Vivus LLC | $21.25 | 2024 | Pancreaze |
| Sandoz INC. | $21.17 | 2024 | Hyrimoz |
| Boston Scientific Corporation | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.